Febuxostat Transfer in Cord Blood and Breast Milk During Pregnancy

A clinical case report published in the Journal of Pharmaceutical Health Care and Sciences has tracked the transfer of febuxostat into umbilical cord blood and breast milk.

Researchers evaluated the clinical course and drug concentrations of a 30-year-old woman with familial juvenile hyperuricemic nephropathy. The patient strongly desired to have children while managing her underlying hyperuricemia. Medical professionals maintained her treatment regimen of 40 milligrams per day of febuxostat alongside 500 milligrams per day of sodium bicarbonate after confirming her pregnancy at nine weeks gestation. The patient carried the pregnancy to term and delivered at 38 weeks of gestation.

Immediately prior to delivery, before her scheduled medication dose, the maternal plasma concentration of febuxostat was measured at 169 nanograms per milliliter. At birth, four hours after taking her medication, the umbilical cord blood concentration reached 154 nanograms per milliliter. Medical staff observed no major congenital abnormalities at birth, providing initial observational data on how the pharmaceutical compound crosses the maternal-fetal barrier.

  • Placental Crossing: Febuxostat, a medication used to lower uric acid levels, successfully crosses the placental barrier, as shown by measurable concentrations in umbilical cord blood at delivery.
  • Breast Milk Transfer: The drug also passes into breast milk, with concentrations peaking at 81 nanograms per milliliter approximately seven hours after oral maternal dosing.
  • Infant Monitoring: While the infant exhibited no major congenital abnormalities or functional growth issues at a one-month checkup, researchers emphasize that more data is necessary to determine safety.

Following delivery, the patient chose to breastfeed her newborn while continuing her oral daily dose of 40 milligrams of febuxostat. Investigators measured drug concentrations in her breast milk across multiple intervals to map the pharmacokinetic profile during lactation. Readings recorded 37 nanograms per milliliter immediately before dosing, 40 nanograms per milliliter one hour after dosing, 58 nanograms per milliliter at 3.5 hours, and 81 nanograms per milliliter at seven hours post-dose.

During the infant’s one-month checkup, clinicians noted a deformity of the second toenail. However, the medical team could not confirm any direct association between the nail finding and a congenital malformation from the drug exposure. The infant exhibited no functional abnormalities, and no problems with overall growth or physical development were documented by the pediatric staff.

Timing / Specimen Maternal Dose Measured Concentration
Pre-delivery Maternal Plasma 40 mg/day oral 169 ng/mL
Breast Milk (Pre-dose) 40 mg/day oral 37 ng/mL
Breast Milk (3.5h post-dose) 40 mg/day oral 58 ng/mL

Nishimura and colleagues, no epidemiological studies or case reports had examined the administration of febuxostat during human pregnancy or breastfeeding.

Because clinical data regarding perinatal safety remains extremely limited, patients managing hyperuricemia or familial juvenile hyperuricemic nephropathy must consult qualified nephrologists and obstetricians before considering pregnancy or lactation while on this medication. Immediate medical evaluation is required if infants exhibit unexpected developmental delays, structural abnormalities, or feeding difficulties following perinatal drug exposure.

The study authors concluded that further clinical investigations and larger observational cohorts remain required before drawing definitive conclusions regarding the overall risk profile for infants exposed to febuxostat during gestation and lactation.

  • Journal of Pharmaceutical Health Care and Sciences.
Photo of author

Priya Deshmukh - Senior Editor, Health

Priya Deshmukh Senior Editor, Health Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.

Cignetti: Indiana ‘Ripped the Heart Out’ of Ohio State, Defends CFP Resume

Mollie Byrnes Donates to Montserrat College Creative Employment Initiative